Market Research Industry Reports

Ovarian Cancer [2017]: Bulletin #1

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS



This update bulletin presents key opinion leader (KOL) insights on recent events in the ovarian cancer treatment landscape. Topics covered include; the US approval and launch of Tesaros PARP inhibitor Zejula (niraparib) for the maintenance treatment of recurrent ovarian cancer that is in complete or partial response to platinum-based chemotherapy; the Phase III ARIEL3 trial of Clovis PARP inhibitor Rubraca (rucaparib) meeting its primary endpoint of improved progression-free survival (PFS) in platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer; and the new data from the Phase I/II ECHO-204 trial evaluating Incytes IDO1 inhibitor epacadostat plus Bristol-Myers Squibbs PD-1 inhibitor Opdivo (nivolumab) in multiple solid tumours types, including ovarian cancer, presented at ASCO 2017.





Business Questions:

How do KOLs view the US approval of Tesaros Zejula?
How will Zejula be used in the treatment of ovarian cancer?
How will oncologists choose between the PARP inhibitors, and how is their comparative efficacy viewed, in the platinum-sensitive, maintenance setting?
How do the KOLs interpret the results of the ARIEL3 trial of Clovis Rubraca, and how do they view the overall significance of these data?
Where do KOLs see Rubraca fitting into the ovarian cancer treatment algorithm in the longer term?
How do KOLs view the findings from the ECHO-204 trial of Bristol-Myers Squibbs PD-1 inhibitor Opdivo in combination with Incytes IDO1 inhibitor epacadostat?
How do KOLs view the overall potential for combining an IDO inhibitor with a PD-1 inhibitor in the treatment of ovarian cancer and what could increase the chance of success for such combinations?

Ovarian Cancer - Pipeline Review, H1 2018

Ovarian Cancer - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2018, provides an overview of the Ovarian Cancer

USD 2500View Report

Polycystic Ovarian Syndrome Global Clinical Trials Review, H1, 2018

Polycystic Ovarian Syndrome Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Polycystic Ovarian Syndrome Global Clinical Trials Review, H1, 2018 provides an overview of Polycystic Ovarian Syndrome clinical trials

USD 2500View Report

Ovarian Cancer - Pipeline Review, H1 2018

Ovarian Cancer - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2018, provides an overview of the Ovarian Cancer

USD 2500View Report

Ovarian Cancer: KOL Insight

How will new combination regimens impact the ovarian cancer treatment landscape PARP inhibitors are firmly entrenched in the treatment algorithm for ovarian cancer, and their role continues to diversify.

USD 8495View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 1045
  • Enterprise Wide Licence    USD 2575
$ 1045

Reports Details

Published Date : Jul 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube